

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



AL

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/21	A1	(11) International Publication Number: WO 97/41884 (43) International Publication Date: 13 November 1997 (13.11.97)
(21) International Application Number: PCT/IB97/00490 (22) International Filing Date: 5 May 1997 (05.05.97) (30) Priority Data: PN 9765 9 May 1996 (09.05.96) AU PO 3959 3 December 1996 (03.12.96) AU PO 4387 24 December 1996 (24.12.96) AU (71) Applicant: PHARMA PACIFIC PTY. LTD. [AU/AU]; Bayside Plaza, Suite 6002, 378 Bay Street, Brighton-Le-Sands, NSW 2216 (AU). (72) Inventor: TOVEY, Michael, Gerard; 7, rue Lagrange, F-75005 Paris (FR).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: METHOD OF TREATMENT (57) Abstract Interferon composition for oromucosal contact to stimulate host defense mechanisms or an immune response in a mammal with a stimulating amount of the interferon which exceeds parenterally administered amounts of interferon, methods of treatment with such compositions and uses of interferon in the preparation of such oromucosal compositions.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

METHOD OF TREATMENT

This invention relates to methods of stimulation of host defense mechanisms against pathological conditions in a mammal by administration of high doses of interferon via the oromucosa. In particular, the invention is applicable to methods of treatment of autoimmune, neoplastic, neurodegenerative, parasitic, and viral diseases.

BACKGROUND OF THE INVENTION

Alpha interferons are used widely for the treatment of a variety of haematological malignancies including hairy cell leukaemia, chronic myelogenous leukaemia, low grade lymphomas, cutaneous T-cell lymphomas, and solid tumours such as renal cell carcinoma, melanoma, carcinoid tumours and AIDS-related Kaposi's sarcoma (Guttermann, J.U., *Proc. Natl. Acad. Sci. USA*, 1994 **91**: 1198-1205). Antitumour effects are usually seen at high dosage levels, often of the order of tens of millions of units of interferon- α (IFN- α), administered by parenteral injection. Interferon- β (IFN- β) is licensed for clinical use in treatment of relapsing-remitting multiple sclerosis and chronic viral hepatitis B and C.

Interferon- α and Interferon- β are both Type I interferons. Type I interferons are a large class of naturally-occurring cytokines which includes over 16 subclasses of IFN- α , plus IFN- β and IFN- ω . The Type I interferons bind to a single cell surface receptor, and stimulate a complex sequence of signal transduction events leading ultimately to anti-viral, anti-proliferative and other immunomodulatory effects, cytokine induction, and HLA class I and class II regulation (Pestka *et al.*, *Annu. Rev. Biochem.*, 1987 **56**: 727). Individual subtypes of Type I IFN vary in activity. The most frequently observed amino acid at each position has been identified by scanning of a large number of allelic subtypes of IFN- α , and a synthetic Type I interferon having the consensus sequence has been synthesized (Alton *et al* in "The Biology of the Interferon System", E. de Maeyer and H. Schellekens eds. Elsevier (1983) 1991-

128). This consensus interferon is commercially available (Infergen; Amgen, Inc.), and has recently been shown to have higher activity (w/w) than IFN- α 2a or IFN- α 2b; it has been suggested that consensus IFN would be clinically superior to IFN of an individual natural subtype (Blatt *et al*, *J. Interferon and Cytokine Research*, 1996 16: 489-499).

Although a number of routes of administration, including intravenous, subcutaneous, intramuscular, topical, and intralesional injection, are commonly employed for the administration of type I interferons, the oral route has not been generally used, because interferons are proteins which are considered to be inactivated by proteolytic enzymes and which are not absorbed appreciably in their native form in the gastrointestinal tract. Indeed a number of studies have failed to detect interferons in the blood following oral administration (Cantell and Pyh  la, *J. Gen. Virol.*, 1973 20: 97-104; Wills *et al*, *J. IFN Res.*, 1984 4: 399-409; Gilson *et al*, *J. IFN Res.*, 1985 5: 403-408).

It is widely considered that in order to obtain the maximum therapeutic effect, the highest possible dose of interferon should be used. Although the availability of recombinant material has meant that very high dose levels are feasible, in practice it has been found that the side-effects of interferon administration have severely limited the dose of interferon which can be used and the duration of treatment. These side-effects include severe malaise and depression, leading in some cases even to suicide. A recent editorial by Hoofnagle in the New England Journal of Medicine has summarized these problems (Hoofnagle, J. H., and Lau, D., *New Eng. J. Medicine* 1996, 334:, 1470-1471). Meta-analysis of the effect of interferon- α treatment in patients with hepatitis B e antigen-positive chronic hepatitis B has shown a rate of remission of 25 to 40%, in patients with typical chronic hepatitis B, treated with 5 million IU daily or 10 million IU three times per week for 3 to 6 months. These results fall short of a cure, however, as most patients remain positive for hepatitis surface antigen and harbour viral DNA when tested by the polymerase chain reaction. Furthermore, these doses of interferon are poorly tolerated, and 10% to 40% of

patients require dose reduction due to intolerable side effects. At a well-tolerated dose of 1 million IU daily, the remission rate is, however, only 17% (Perrillo *et al.* *New Eng. J. Medicine*, 1990, 323:, 295-301). In patients with chronic hepatitis C, sustained long-term improvement is associated with the loss of HCV RNA, which occurs in only 5 10 to 20% of patients treated with a dose of 3 million IU three times per week for 6 months (Hoofnagle and Lau, *op. cit.*). In patients with cancer, significant response rates are usually seen only at the highest tolerated doses of interferon- α . Thus in patients with multiple myeloma, for example, the response rate is 50% in patients treated with 20 to 30 million IU daily, and only 15 to 20% in patients treated with 3 10 million IU. Very few patients are able, however, to tolerate the high-dose regimen for more than a short period of time (Ahre *et al.* *Eur. J. Hematol.*, 1988, 41:, 123-130). Thus clearly there is a need in the art for means which would enable the administration of high dose interferon without the induction of severe side-effects.

There have been a number of anecdotal reports of efficacy of low doses 15 of interferon administered as a nasal spray or as an oral liquid formulation in the treatment of a variety of viral conditions, particularly influenza. However, in most of these reports the interferon preparations used were relatively crude. A placebo-controlled trial of relatively high dose intranasal interferon for treatment of rhinovirus infection showed that the treatment was effective, but that there was a significant 20 incidence of side-effects (Hayden *et al.*, *J. Infect. Dis.*, 1983 148: 914-921). Similarly, although a number of studies including two randomized double-blind clinical trials (Douglas *et al.*, *New Engl. J. Med.*, 1986 314: 65-80; Hayden *et al.*, *New Engl. J. Med.*, 1986 314: 71-75) have demonstrated the efficacy of nasally administered high dose recombinant interferon- α 2 in protecting exposed subjects against rhinovirus 25 infections, these studies provided no evidence for a systemic effect.

More recently a series of patent specifications has described the use of low doses of orally-administered interferon of heterologous species origin for the treatment of infectious rhinotracheitis ("shipping fever") in cattle, and of feline leukaemia, and also treatment of other conditions, for enhancement of efficiency of

vaccines; for improving the efficiency of food utilisation; and for prevention of bovine theileriosis. See U.S. Patent No. 4,462,985, Australian Patent No. 608519, Australian Patent No. 583332 and U.S. Patent No. 5,215,741 respectively. In addition U.S. Patent No. 5,017,371 discloses the use of interferon in this way for treatment of side-effects of cancer chemotherapy or radiotherapy. In these specifications, the interferon used was human interferon- α prepared by the method of Cantell, administered in phosphate buffered saline, at a dose of 0.01 to 5 IU per pound body weight. While these specifications suggest that such low doses of interferon administered to the oropharyngeal mucosa, preferably in a form adapted for prolonged contact with the oral mucosa, may be efficacious for treatment of a wide variety of conditions including cancer, the experimental evidence for conditions other than shipping fever, feline leukaemia, canine parvovirus and theileriosis is largely anecdotal. In particular, no properly controlled trials of this treatment in any animal model for human cancers are presented.

More recent studies on the effects of very low doses of interferon administered by the oral or oropharyngeal mucosa have been reviewed (Bocci, *Clin. Pharmacokinet.*, 1991 **21**: 411-417; *Critic. Rev. Therap. Drug Carrier Systems*, 1992 **9**: 91-133; Cummins and Georgiades, *Archivum Immun. Therap. Exp.*, 1993 **41**: 169-172). It has been proposed that this type of treatment is particularly useful for treatment of HIV infection, and can at least improve quality of life in AIDS patients (Kaiser *et al*, *AIDS*, 1992 **6**: 563-569; Koech *et al*, *Mol. Biol. Ther.*, 1990 **2**: 91-95). However, other reports indicate that such treatments provide no clinical benefit. A Phase I study of use of oral lozenges containing low doses of interferon for treatment of hepatitis B has also been reported (Zielinska *et al*, *Archiv. Immunol. Therap. Exp.*, 1993 **41**: 241-252).

In contrast, International Patent Application No. WO 95/27499 by Brigham and Women's Hospital showed that Interferon- β administered by gastric intubation could at least partly suppress development of autoimmune diseases such as Type I diabetes, multiple sclerosis and autoimmune arthritis in well-recognized animal

models, if given before the inducing antigen. Interferon- β given by this route or intraperitoneally in conjunction with intragastric "bystander" antigen was even more effective in inducing tolerance. This suggests that interferon- β is effective in enhancing the induction of oral tolerance, rather than in inducing either humoral or cellular responses to exogenous antigen.

In Australian Provisional Patent Application No. PN 9765, low doses of interferon administered to the oropharyngeal cavity by the oromucosal route were shown to be effective in protecting mice against challenge with highly metastatic tumour cells. The quite exceptional nature of these results, together with the fact that very few substances exhibit activity against these very aggressive tumours, indicates that administration of interferon to the oropharyngeal cavity is useful in the treatment of cancer. Low oromucosal doses of interferon were also effective in treating mice injected intraperitoneally with encephalomyocarditis virus (EMCV), which normally gives rise to a rapidly progressing fatal disease characterized by central nervous system involvement and encephalitis. Although this system is a very severe test of antiviral activity, the oromucosal route for administration of interferon was comparably effective to intraperitoneal administration.

SUMMARY OF THE INVENTION

This invention provides a method for stimulating host defense mechanisms in a mammal via the oromucosal administration of an interferon at doses higher than those which induce a pathological response when administered parenterally, generally greater than about 20×10^6 IU of homologous interferon- α in man. For another type of interferon the dose that will induce a pathological response may differ from that induced by homologous interferon- α in man.

In one aspect, the invention may be considered as a method of stimulating the immune response in a mammal by administering to the mammal an immunostimulating amount of an interferon via oromucosal contact, said amount

being in excess of a dose of the same interferon as that which induces a pathological response when administered parenterally.

Alternatively, the invention provides a method for increasing the therapeutic index of interferon by administering interferon oromucosally.

5 The oromucosal administration may involve administering an effective dose of interferon in a single dose or the effective dose may be administered in a plurality of smaller doses over a period of time sufficient to elicit immunostimulation equivalent to that of a single dose. Likewise, the dose of interferon may be administered continuously over a period of time sufficient to induce an effect
10 equivalent to that of a single dose.

 In its applied aspects, the invention provides a method for treating autoimmune, mycobacterial, and neurodegenerative diseases, neoplastic conditions and viral infections, via administering to the mammal an effective amount of an interferon via oromucosal contact, said amount being in excess of the dose of the same
15 interferon which induces a pathological response when parenterally administered. In particular, the invention provides a method for treating autoimmune diseases such as arthritis, Type I diabetes, lupus, and multiple sclerosis, mycobacterial diseases such as leprosy and tuberculosis, neurodegenerative disorders such as spongiform encephalitis and Creutzfeldt-Jakob disease, parasitic diseases such as malaria, and viral diseases
20 such as cervical cancer, genital herpes, hepatitis B and C, HIV, HPV, and HSV-1 and 2.

 The invention also provides a method for treating multiple myeloma, hairy cell leukemia, chronic myelogenous leukemia, low grade lymphoma, cutaneous T-cell lymphoma, carcinoid tumors, cervical cancer, sarcomas including Kaposi's
25 sarcoma, kidney tumors, carcinomas including renal cell carcinoma, hepatic cellular carcinoma, nasopharyngeal carcinoma, hematologic malignancies, colorectal cancer, glioblastoma, laryngeal papillomas, lung cancer, colon cancer, malignant melanoma, and brain tumors including malignant brain tumors. In one embodiment, the method is generally applicable in the treatment of tumors of non-viral etiology.

In another embodiment, the invention provides a pharmaceutical composition for oromucosal administration comprising a therapeutically effective amount of at least one interferon, said amount exceeding that amount which elicits a pathological response when administered parenterally, and a pharmaceutically acceptable carrier. The composition may be provided as a solution, tablet, lozenge, gel, syrup, paste, or controlled release oromucosal delivery system. Optionally, the composition may contain buffers, stabilizers, thickening agents, absorption and viscosity enhancers, and the like.

In one embodiment, the pharmaceutical composition is provided in unit dosage form having from about 20×10^6 IU to about 1000×10^6 IU of interferon, preferably from about 20×10^6 IU to about 500×10^6 IU, preferably from about 50×10^6 IU to about 500×10^6 IU.

The method may be practiced either as the sole therapeutic approach, or as an adjunct to radiation therapy, chemotherapy, or with other cytokines, such as interleukin-2, 12, or 15, or with IFN-inducers.

The method is preferably conducted using a Type I or Type II IFN, selected from α , β , γ , ω , and consensus interferons, most preferably with a recombinant IFN- α .

DETAILED DESCRIPTION OF THE INVENTION

The invention will now be described in detail by way of reference only using the following definitions and examples. All patents and publications referred to herein are expressly incorporated by reference.

Definitions

As used herein, "interferon" refers to a Type I or Type II interferon, including those commonly designated as α , β , γ , and ω , and mixtures thereof, including the consensus sequence. Interferons are available from a wide variety of commercial sources and are approved for the treatment of numerous indications. The interferon may be from natural sources, but is preferably a recombinant product. For

the purposes of the invention, the term "interferon" also includes polypeptides or their fragments which have interferon activity, and chimeric or mutant forms of interferon in which sequence modifications have been introduced, for example to enhance stability, without affecting the nature of their biological activity, such as disclosed in
5 U.S. Patent Nos. 5,582,824, 5,593,667, and 5,594,107 among others.

By the term "high dose" is meant a dose greater than the maximum dose usually tolerated of the same interferon when given by a parenteral route, such as intravenous or intraperitoneal administration. As currently envisioned, a high dose of interferon is greater than about 20×10^6 IU of homologous interferon- α for a 70 kg
10 adult. Preferably the dose is greater than about 30×10^6 IU. In a particularly preferred form of the invention the total dose is from about 50×10^6 IU to about 1000×10^6 IU, more preferably from about 50×10^6 IU to 500×10^6 IU. As used herein, "high dose" is generally considered to be a therapeutically effective dose when administered oromucosally, which if given parenterally would induce a pathological response, either
15 manifested by the appearance of unacceptable side effects or surrogate markers of toxicity. The definition of high dose is of necessity flexible, since it may vary depending, *inter alia*, upon the individual sensitivity, size, weight, and age of the patient, the nature and severity of the condition being treated, the particular interferon used and the specific vehicle of administration. A physician treating a patient with a
20 particular interferon will be able to *readily* identify the suitable high dose range for the patient to be treated.

Optionally the interferon may be administered concurrently with an inducer of interferon synthesis and release. The inducer may be administered together with the interferon, or may be administered separately. Inducers of interferon include,
25 for example, polynucleotides such as poly I:C; preferably a low molecular weight, orally administrable interferon inducer is used. Suitable inducers are known in the art, for example, Tilorone (U.S. Patent No 3592819; Albrecht *et al*, *J. Med. Chem.* 1974

17: 1150-1156) and the quinolone derivative Imiquimod (Savage *et al*; *Brit. J. Cancer*, 1996 74: 1482-1486).

5 The methods and compositions of the invention may optionally be used in conjunction with one or more other treatments for the specific condition, and the attending physician or veterinarian will readily be able to select such other treatment as may be appropriate in the circumstances.

In one embodiment, the invention provides a method of treatment of a neoplastic condition in a mammal, comprising the step of administering interferon as described above. The neoplastic condition may be metastatic cancer.

10 While the method of the invention may be used without concurrent treatment with other agents, it is contemplated that this embodiment of the invention will be particularly useful in the following settings:

- a) as adjuvant therapy, subsequent to surgery, chemotherapy, or radiotherapy given by standard protocols;
- 15 b) for treatment of interferon-sensitive neoplasias, the method of the invention is utilized either alone or in conjunction with conventional chemotherapy or radiotherapy; and
- c) for treatment of interferon-resistant neoplasias, the method of the invention is utilized either alone or most preferably in conjunction with conventional
20 chemotherapy or radiotherapy.

The above methods are directed at inducing and/or maintaining remission of disease. By "in conjunction with other treatment" is meant that the interferon is administered before, during and/or after the radiotherapy or other chemotherapy. The most suitable protocol will depend on a variety of factors, as
25 discussed below.

In particular, it is contemplated that the method of the invention will preferably be used in conjunction with at least one other treatment selected from the group consisting of chemotherapy using cytostatic drugs, one or more other cytokines which have anti-cancer activity but which have a different mechanism of action from

that of interferon, anti-angiogenic agents, and agents which potentiate the activity of interferon. Preferably the second cytokine is interleukin-1 (IL-1), interleukin-2 (IL-2) interleukin-12 (IL-12), or interleukin-15 (IL-15); preferably the angiogenesis inhibitor is AGM-1470; preferably the interferon-potentiating treatment is hyperthermia or arginine butyrate.

Preferred cytostatic drugs to be administered in conjunction with interferon include but are not limited to cyclophosphamide, cisplatin, carboplatin, carmustine (BCNU; N,N-Bis(2-chloroethyl)-N-nitrosourea), methotrexate, adriamycin, α -difluoromethylornithine, and 5-fluorouracil.

The neoplastic conditions susceptible to this method include but are not limited to cancers which respond to parenteral administration of high doses of IFN- α , such as hematological malignancies, multiple myeloma, hairy cell leukemia, or chronic myelogenous leukemia, low grade lymphomas, cutaneous T cell lymphoma, solid tumors such as renal cell carcinoma and melanoma, carcinoid tumors, or AIDS-associated Kaposi's sarcoma, in particular malignant tumors of non-viral etiology. The viral condition may be an acute or fulminant infection, such as rhinovirus, influenza, herpes varicella, herpes zoster, dengue fever, or viral encephalitis including but not limited to measles virus encephalitis, Murray Valley encephalitis, Japanese B encephalitis, tick-borne encephalitis and Herpes encephalitis; haemorrhagic fevers such as Ebola virus, Marburg virus, Lassa fever; Hanta virus infections, and other viral infections thought to be transmitted from animals to humans, such as equine morbillivirus. In many of these conditions there is no treatment and/or vaccine presently available, and supportive treatments may be inadequate. Alternatively the viral condition may be the result of chronic infection, such as hepatitis B, hepatitis C, hepatitis D or other forms of viral hepatitis, and CMV, HIV, HPV, and HSV I & II infection. Hepatitis B and hepatitis C are both currently treated with parenteral interferon; long-term interferon treatment in HIV infection which has progressed to AIDS is under clinical trial.

In a second embodiment, the disease to be treated is malaria, and again a Type I or II interferon is administered as described above. The causative organism of the malaria may be *Plasmodium malariae*, *Plasmodium vivax*, *Plasmodium falciparum* or *Plasmodium ovale*. It is particularly contemplated that the method of the invention
5 will protect against progression of malaria to the cerebral form.

In a third embodiment, the invention provides a method of treatment of autoimmune disorders such as HIV, rheumatoid arthritis, and multiple sclerosis, whether of the relapsing-remitting or the chronic progressive type or immunodeficiencies such as AIDS, comprising the step of administering an interferon
10 as described above.

Again the method and dosage form of the invention may be used in conjunction with other treatments. For example, for herpes virus infection acyclovir or ganciclovir may be used. For HIV infection azidothymidine (zidovudine) or one or more other HIV reverse transcriptase inhibitors, and/or HIV protease inhibitors may be
15 used.

In the preparation of the pharmaceutical compositions of this invention, a variety of vehicles and excipients for IFN may be used, as will be apparent to the skilled artisan. Representative formulation technology is taught in, *inter alia*, Remington: The Science and Practice of Pharmacy, 19th ed., Mack Publishing Co.,
20 Easton, PA, 1995, and its predecessor editions. The IFN formulation may comprise stability enhancers, such as glycine or alanine, as described in U.S. Patent No. 4,496,537, and/or one or more carriers, such as a carrier protein. For example, for treatment of humans pharmaceutical grade human serum albumin, optionally together with phosphate-buffered saline as diluent, is commonly used. Where the excipient for
25 IFN is human serum albumin, the human serum albumin may be derived from human serum, or may be of recombinant origin. Normally when serum albumin is used it will be of homologous origin.

The IFN may be administered by any means which provides contact of the IFN with the oromucosal cavity of the recipient. Thus it will be clearly understood

that the invention is not limited to any particular type of formulation. The present specification describes administration of IFN deep into the oromucosal cavity; this may be achieved with liquids, solids, or aerosols, as well as nasal drops or sprays. Thus the invention includes, but is not limited to, liquid, spray, syrup, lozenges, buccal
5 tablets, and nebuliser formulations. A person skilled in the art will recognize that for aerosol or nebuliser formulations the particle size of the preparation may be important, and will be aware of suitable methods by which particle size may be modified.

In one aspect, the interferon is administered in a single dose. Alternatively, the interferon is administered in a plurality of lower doses, distributed
10 over time, so that the net effect is equivalent to the administration of the single higher dose. One approach to this delivery mode is via the provision of a sustained or controlled release device adhered to or implanted in the oromucosal cavity and designed to release interferon over time in an amount equivalent to a single high dose.

Representative formulations of interferon for oromucosal use include the
15 following (all % are w/w):

Tablet: Dextrose BP 45 %; gelatin BP 30 %; wheat starch BP 11%;
carmellose sodium BP 5 %; egg albumin BPC 4 %; leucine USP 3 %; propylene
glycol BP 2%; and 50×10^6 IU IFN- $\alpha 2$. The tablet may be used as is and allowed to
slowly dissolve in the mouth or may be dissolved in water and held in the mouth in
20 contact with the oromucosa as needed.

An interferon paste may be prepared, as described in U.S. Patent No.
4,675,184, from glycerin 45%, sodium CMC 2%, citrate buffer (pH 4.5) 25%, distilled
water to 100%, and 50×10^6 IU IFN- $\alpha 2$. The interferon paste may be adhered to the
buccal mucosa.

25 Likewise, a gargle or a syrup may be prepared by adding the desired amount of interferon to a commercially available mouthwash or cough syrup formulation.

Within the specific dose ranges referred to above, the optimal treatment in any individual case will depend on the nature of the condition concerned, the stage

of disease, previous therapy, other continuing therapy, the general state of health of the mammal, the sensitivity of the subject to interferon, *etc.*, and therefore will be at the physician's or veterinarian's discretion, bearing in mind all these circumstances. The length of treatment will of course vary with the condition being treated, for example, treatment of a slow-growing cancer, such as prostate cancer, would be expected to involve a different course of treatment than treatment of a rapidly growing cancer, such as hepatic cellular carcinoma. Similarly, an acute infection such as caused by Ebola virus would be expected to involve a different course of treatment than a chronic condition, such as hepatitis.

10 The effective dose disclosed herein is one which may generate a pathological response in the mammal when administered parenterally, but is both effective and either non-toxic or less toxic when administered oromucosally. A pathological response may be acute, chronic, or cumulative, and may be manifested by changes in blood chemistry, such as leukopenia, bone marrow depression, or other histological parameters. As used herein, a pathological response includes adverse side effects, such as fever, malaise, or flu-like symptoms, vascular reactions, such as phlebitis, and local inflammatory reactions at the site of injection. Such responses will vary considerably among the patient population in view of individual variations in sensitivity to interferon.

20 For many patients, it is expected that oromucosal doses will exceed those known to be tolerated in existing approved parenteral protocols. In one embodiment, the total dose may be administered in multiple lower doses over time, or even may be delivered continuously or in a pulsatile manner from a controlled release device adhered to or implanted in the oromucosa.

INTERFERONS AND INTERFERON FORMULATIONS

Mouse IFN- α/β

Mouse IFN- α/β (Mu IFN- α/β) was prepared from cultures of C243-3 cells induced with Newcastle disease virus (NDV) and purified as described previously (Tovey *et al*, *Proc. Soc. Exp. Biol. and Med.*, 1974 146: 809-815). The preparation used in this study had a titer of 4×10^6 International Units (IU)/ml and a specific activity of 5×10^7 IU/mg protein as assayed on mouse 929 cells challenged with vesicular stomatitis virus (VSV) as described previously (Tovey *et al*, *Proc. Soc. Exp. Biol. and Med.*, 1974 146: 809-815). The preparation was standardized against the international reference preparation of murine IFN- α/β of the National Institutes of Health (NIH) (G-002-9004-5411).

Human IFN- α -1-8

Recombinant human IFN- α 1-8 (Hu IFN- α 1-8; BDBB lot no. CGP 35269-1, Ciba-Geigy, Basel, Switzerland) was prepared and purified as described previously (Meister *et al*, *J. Gen. Virol.*, 1986 67: 1633-1643). The preparation used in this study had a titer of 70×10^6 IU/ml on homologous human WISH cells challenged with VSV as described previously (Tovey *et al*, *Nature*, 1977 267: 455-457), and a titer on heterologous mouse L929 cells of 1×10^6 IU/ml. The preparation was standardized against both the NIH human IFN- α international reference preparation (G-023-901-527) and the NIH murine IFN- α/β standard (G-002-9004-5411). The specific activity of the IFN preparation was 2×10^8 IU/mg protein.

RECOMBINANT MURINE INTERFERON- α

Recombinant murine interferon- α was purchased from Life Technologies Inc. The preparation used in this study (lot no. HKK404) had a titer of 6×10^6 IU/ml and a specific activity of 6×10^8 IU/mg protein as assayed on mouse L929 cells challenged with VSV (Tovey *et al*, *Proc. Soc. Exp. Biol. Med.*, 1974, 146:406-415).

RECOMBINANT MURINE INTERFERON β

Recombinant murine interferon β was purchased from R & D Systems Inc. The preparation used in this study (lot no. 1976-01S) had a titer of 3.2×10^4 IU/ml and a specific activity of 8×10^6 IU/mg protein as assayed on mouse L929 cells challenged with VSV (Tovey et al, proc. Soc. Exp. Biol. Med., 1974, 146:406-415).

RECOMBINANT MURINE INTERFERON γ

Recombinant murine interferon γ was purchased from R & D Systems Inc. The preparation used in this study (2580-03SA) had a titer of 2×10^5 IV/ml and a specific activity of 1×10^7 IU/mg protein as assayed on mouse L929 cells challenged with VSV (Tovey et al, Proc. Soc. Exp. Biol. Med., 1974, 146:406-415).

All the interferon preparations were titrated simultaneously in the same assay and standardized against the international reference preparation of murine interferon α/β of the US National Institutes of Health (G-002-9004-5411).

Both murine interferon α/β and recombinant murine interferons were taken up in FerimmuneTM excipient prior to administration.

EXCIPIENT

Interferon preparations were diluted either in phosphate buffered saline (PBS) containing bovine serum albumin (BSA) or in the proprietary excipient described below. Bovine serum albumin fraction V (RIA grade; immunoglobulin free; Cat. no. A7888; Sigma; USA) was dissolved at a final concentration of 100 μ g/ml in PBS (pH 7.4) and sterilized by filtration (0.2 μ , Millex-GV, Millipore, USA).

In the experiments described herein the interferon preparations were diluted in a proprietary excipient. The excipient used was as follows, supplied in the form of tablets (FerimmuneTM, Pharma Pacific):

	%w/w	mg/tablet
Dextrose (Glucose) BP**	44.67***	55.84
Gelatin BP**	30.06	37.58
Wheat Starch BP**	11.31	14.14
Carmellose Sodium BP**	4.96	6.20
Egg Albumen BPC**	4.03	5.04
Leucine USP	3.00	3.75
Propylene Glycol BP	1.88	2.35
Dextran 40** (as Dextran 40 Injection BP)	0.06	0.08
Sodium Phosphate BP	0.03	0.04
Sodium Chloride BP	0.01	0.01
Sodium Acid Phosphate BP	0.01	0.01
Total	100.02	125.04

** Calculated on an anhydrous basis

*** Derived from:

Dextrose (Glucose) BP (anhydrous) 44.64%

Glucose BP (as Dextran 40 Injection BP) 0.03%

5

A single tablet was dissolved in 1.5 ml phosphate buffered saline, centrifuged at 16,000 g for 15 m, and then sterile filtered (0.2 μ , Millex-GV, Millipore, USA), and stored at 4°C prior to use. Excipient was prepared daily prior to use.

10 INTERFERON DELIVERY SYSTEM

Preliminary experiments showed that the application of 5 μ l of crystal violet to each nostril of a normal adult mouse using a P20 Eppendorf micropipette

resulted in an almost immediate distribution of the dye over the whole surface of the oropharyngeal cavity. Staining of the oropharyngeal cavity was still apparent some 30 minutes after application of the dye. Essentially similar results were obtained using ¹²⁵I-labeled recombinant human IFN- α 1-8 applied in the same manner. This method of administration was therefore used in all subsequent experiments.

For the purposes of the animal experiments described in this specification, it will be clearly understood that the expressions "oromucosal" or "oropharyngeal" or "intranasal/oral" or "intranasal plus oral" or "in/or" with reference to the route of administration of IFN is to be taken to mean administration of the IFN preparation deep into the nasal cavity so that it is rapidly distributed into the oromucosal cavity, *i.e.* the mouth and throat of the recipient mammal, so as to make contact with the mucosa lining this cavity.

EMCV (ENCEPHALOMYOCARDITIS VIRUS)

Batch: Lot no. 095001

15 Expiration Date: December 1997

Preparation: EMCV strain JH was propagated on mouse L929 cells using methods described previously (Gresser I. Bourali C, Thomas MT, Falcoff E. Effect of repeated inoculation of interferon preparations on infection of mice with encephalomyocarditis virus. Proc Soc Exp Biol Med 1968 Feb; 127:491-6)

20 Characterization: The virus stock used in this study had a titer of $5 \times 10^{8.62}$ TCID₅₀ on mouse L929 cells.

Storage: Stock EMCV was stored at -70°C. A power cut on day 1 of the Virus Titration necessitated transfer temporarily to back-up storage at approximately the same temperatures. The material

25 remained frozen at all times. On day +8 of the Virus Titration the -70°C freezer increased in temperature to -60°C. Diluted EMCV

was prepared immediately before use and was kept on ice or in the animal room refrigerator until use.

FRIEND ERYTHROLEUKAEMIA CELLS

The IFN- α/β -resistant clone, 3C18, of Friend erythroleukaemia cells (FLC) was obtained from Dr E. Affabris, Rome and is described in detail by Affabris *et al*, 1982 (*Virology*, **120**: 441-452). These cells were subsequently maintained by *in vivo* passage. Briefly, DBA/2 mice were inoculated by intraperitoneal injection (ip) with approximately 100 LD₅₀ of 3C18 cells and one week later the tumor cells were harvested from the peritoneum of the mice, counted and other mice were again inoculated with 100 LD₅₀ of 3C18 cells. This procedure was repeated for 60 to 100 passages. It has been shown that the 3C18 cells used at the 60th to 100th *in vivo* passage are highly metastatic for the liver and spleen (Gresser *et al*, *Int. J. Cancer*, 1987 **39**: 789-792). The phenotype of IFN resistance was confirmed routinely by cultivating the *in vivo* passaged cells *in vitro* in the presence of IFN- α/β (Belardelli *et al*, *Int. J. Cancer*, 1982 **30**: 813-820).

L1210R6 CLONE & EL4 TRANSPLANTABLE TUMOR

The interferon- α/β -resistant clone, L1210R6, of L1210 lymphoma cells was isolated in our laboratory (Gresser *et al*, 1974, Interferon and cell division. IX. Interferon-resistant L1210 cells : Characteristics and Origin. *J. Nat. Cancer Inst.*, **52**:553-559).

The EL4 transplantable tumor was originally derived from mice inoculated with the chemical carcinogen 1-2 dimethyl benzanthrein (Gorer, P.A., 1950, *Br. J. Cancer*, **4**:372-381).

The L1210 lymphoma cells were maintained by serial *in vivo* passage in specific-pathogen free DBA/2 mice.

The EL4 tumor was maintained by serial *in vivo* passage in specific-pathogen free C57BL/6 mice.

B16 MELANOMA

The B16 melanoma is a transplantable tumor of spontaneous origin derived from a C57BL/6 mouse (Fidler I.J. and Krippl, M.L. 1977, Science 197, 893-897). The B16 melanoma is a rapidly growing, highly anaplastic, melanin producing tumor which metastasizes principally to the lung. The B16 melanoma is considered to be a good model for rapidly growing, highly aggressive human tumors.

B16 melanoma cells were maintained by serial *in vivo* passage in specific-pathogen free C57BL/6 mice.

ANIMALS

The mice used in this study were obtained from a specific pathogen-free colony (IFFA CREDO, France). They were housed in a specific pathogen-free animal facility at the Institut Federatif CNRS at Villejuif according to EEC standards.

INTERFERON BIOASSAY

Interferon was assayed according to a conventional method. Briefly, samples (20 μ l) were diluted in 80 μ l of Eagle's Minimal Essential Medium (MEM) (Gibco, France) containing 2% heat-inactivated Fetal Calf Serum (FCS) (Gibco, France) and added to each well of a microtitre plate (Falcon, cat. no. 3072) using a multichannel micro-pipette (Finnpipette, Labsystem, 50-300 μ l). WISH or L929 cells (2×10^4 cells/well) were added in 100 μ l of MEM containing 2% FCS and incubated overnight at 37°C in an atmosphere of 5% CO₂ in air (Forma 3029 CO₂ incubator). The cells were then examined for any signs of toxicity using an Olympus IM GLDW inverted microscope equipped with a 10X objective. Samples which did not exhibit detectable toxicity were then subjected to serial two-fold dilutions starting from an initial 1:10 dilution in a total volume of 200 μ l of Eagle's MEM containing 2% FCS, by carrying forward 100 μ l of diluted material with a multichannel micropipette, in a microplate containing 100 μ l per well of fresh Eagle's MEM containing 2% FCS, Appropriate serial two-fold dilutions of the NIH human IFN- α reference standard (G-

023-901-527) or the NIH Mu IFN- α/β reference standard (G-002-9004-5411) were also prepared. WISH or L929 cells (2×10^4 cells/well) in 100 μ l of Eagle's MEM containing 2% FCS were then added to each plate where appropriate and incubated overnight at 37°C in an atmosphere of 5% CO₂ in air. The cell monolayers were then
5 checked for any signs of toxicity and in the absence of any apparent toxicity, the culture was aspirated and replaced with 200 μ l of Eagle's MEM containing 2% FCS containing 100 TCID₅₀ of VSV (2×10^{-4} VSV₂₃ for WISH cells, or 10^{-5} VSV₂₃ for L929 cells). The plates were then incubated overnight at 37°C in an atmosphere of 5% CO₂ in air. The cell monolayers were then examined for specific viral cytopathic
10 effect using an Olympus IM ULWD inverted microscope. Interferon titers were determined from the reciprocal of the dilution which gave 50% protection against specific viral cytopathic effect, and are expressed in international reference units/ml (IU/ml).

Example 1 Effect of High Dose Interferon On Survival Following Lethal Challenge
15 With EMCV (Encephalomyocarditis virus)

The effects of IFN- α doses of 1,000, 10,000 and 100,000 IU given by the oromucosal route was tested in male and female mice injected with a lethal dose of EMCV. Different types of IFN- α were tested, and the effect of administration by the oromucosal route was compared with that of administration by the intraperitoneal (ip)
20 route. In addition to monitoring survival following the lethal challenge, the toxicity of the IFN treatment was monitored using a variety of clinical chemistry and haematological parameters.

Treatment of mice with 10^5 IU of IFN- α by the oromucosal route once a day for 4 days resulted in complete protection of all the animals, when treatment was
25 started after virus infection. One hundred percent of the IFN treated animals were alive and well 100 days after infection with a lethal dose of EMCV (100 LD₅₀) under conditions where all the virus-infected untreated control animals were dead by 7 days.

Based on body weight, treatment of mice with 10^5 IU by the oromucosal route is equivalent to a human dose of 240 million IU, which to our knowledge is considerably more than has ever been administered in man.

As treatment of mice with 10^5 IU of IFN- α by the in/or route resulted in
5 a greater degree of protection than treatment of animals with 10^4 IU of IFN- α , it is probable that even greater effects (against an even greater virus load or tumour burden) will be obtained with even higher doses of IFN- α . So far we have not observed any indication of a plateau in the dose-response curve.

Our results also demonstrate that high to ultra-high doses of IFN given
10 by the in/or route have a highly protective antiviral effect, and that 10^5 IU of IFN- α given by this route gives a complete cure versus the dose of EMCV used. Despite the fact that the doses used were far higher on a body weight basis than those which have ever been administered to humans, being equivalent to 240×10^6 IU, no clinical, biochemical or haematological evidence of toxicity was observed. In contrast, the
15 maximum tolerated dose of parenteral IFN in clinical practice is in the region of 20 to 30×10^6 IU per day.

Example 2 Effect of High Dose IFN- α on Mice Challenged with Highly Metastatic Tumour Cells

20 Groups of 10, six week-old DBA/2 mice were challenged intravenously either with 10^5 Friend erythroleukaemia cells of the interferon-resistant clone 3CI8 or with 10^5 L1210 lymphoma cells (interferon-resistant L1210R cells) on day 0. Following inoculation, the mice were either left untreated, or treated twice a day for 20 days by the in/or route with 10^5 IU of mouse IFN- α/β in a volume of 10 μ l of
25 excipient, or with 10 μ l of excipient alone (control).

Fifty percent of the animals treated with IFN by the in/or route were alive and well 100 days after inoculation with the highly metastatic Friend

erythroleukaemia cells. Thirty percent of the animals treated with IFN by the in/or route were alive and well 100 days after challenge with L1210 lymphoma cells.

Clinical observations suggest that all of the IFN-treated animals alive at 100 days would have survived for a normal lifespan if not sacrificed. Histological examination of organs showed absence of residual tumors. In contrast, all the untreated and control animals were dead by 13 days after challenge with Friend erythroleukaemia cells and 14 days after challenge with L1210 lymphoma cells, respectively.

These results are highly significant, since both of the tumour cell lines used are highly aggressive, and since the challenge dose used was equivalent to approximately 20,000 times the LD₅₀. Furthermore, Friend Leukaemia and L1210 lymphoma are quite different tumour types, in that Friend Leukaemia cells carry a retrovirus, the Friend Leukaemia virus, while L1210 lymphoma is not associated with any known viral etiology. The results obtained with in/or IFN- α therapy of animals inoculated with L1210 lymphoma appear to be equal to or even superior to those obtained with systemic IFN- α therapy in this model (I. Gresser, unpublished results). In our previous study, reported in our Australian provisional application No PN9765, none of the mice inoculated with Friend Leukaemia cells and treated with 100 or 1,000 IU of IFN- α survived, and at a dose of 10,000 IU only 10-20% of the animals were considered to be cured.

Example 3 Effect of High Dose IFN- α on Mice Challenged with Highly Metastatic B16 Melanoma Cells or EL4 Tumour Cells

Groups of 10 six week-old C57B1/6 mice were challenged intravenously with either 10⁵ B16 melanoma cells, or 10⁵ EL4 tumour cells. Following inoculation, the mice were either left untreated, or treated twice a day for 20 days by the in/or route with 10⁵ IU of mouse IFN α/β in a volume of 10 μ l of excipient or with 10 μ l of excipient alone (control).

Thirty percent of the animals treated with IFN by the in/or routes were alive and well 100 days after inoculation with highly metastatic B16 melanoma cells or EL4 tumour cells. In contrast, all the untreated and control animals were dead by 20 days after challenge with B16 melanoma cells and 22 days after challenge with L4 tumour cells, respectively. Clinical observation suggests that all of the IFN-treated animals alive at 100 days would have survived if not sacrificed, even though interferon treatment was stopped at 20 days. Histological examination of organs showed the absence of residual tumor in interferon treated animals sacrificed at 100 days.

10 Example 4 Effect of Oromucosal Interferon Against Vesicular Stomatitis Virus

Groups of ten, 6 week-old mice, from a specific pathogen-free breeding colony were infected intranasally with 100 LD50 of Vesicular Stomatitis virus (VSV) (Tovey et al, Proc. Soc. Exp. Biol. Med., 1974, 146:406-415), in a volume of 10 µl. Seven hours after virus infection mice were either left untreated, or treated once a day for 4 days by the intranasal/oral route with a given dose of murine interferon alpha/beta in a volume of 10 µl of Ferimmune excipient, or with 10 µl of excipient alone (control).

Treatment of adult mice with murine interferon α/β resulted in a marked increase in the percentage of animals surviving infection with a lethal dose of VSV. Thus, 30% of the animals treated with 10,000 IU of interferon α/β were alive 21 days after infection with a lethal dose of VSV, under conditions where all the untreated, or excipient control treated virus-infected animals were dead at 10 days. Clinical observations suggest that most of the interferon-treated animals alive at 21 days will survive.

25

Example 5 Effect of Oromucosal Interferon on Expression of Cellular Proteins

IFN- α is known to induce the expression of a number of cellular proteins following binding of the protein to its cell surface receptor. These proteins are thought to provide a useful marker of IFN action.

We evaluated the effect of IFN- α administered via the in/or route on the expression of three IFN-induced proteins, MHC class I antigens, Ly 6A/E antigen and 2'-5'-oligoadenylate synthetase.

Treatment of DBA-2 mice (H-2K^d) with up to 20,000 IU of Mu IFN- α by the in/or route did not significantly increase H-2-K^d expression on peripheral blood lymphocytes, monocytes or granulocytes under conditions where as little as 20 IU of Mu IFN- α given ip markedly increased the expression of H-2-K^d antigens on both peripheral blood monocytes and granulocytes. Indeed, expression on monocytes was slightly suppressed.

Similarly, treatment of mice with up to 20,000 IU of IFN- α via the in/or route had no significant effect on the expression of Ly6 A/E antigens, the expression of which is markedly enhanced on the surface of a variety of lymphoid cells following parenteral treatment with type I IFN (Dumont *et al*; *J. Immunol*, 1986 137: 201-210). Similar results were obtained with 200 or 20,000 IU of either Mu IFN- α or Hu IFN- α 1-8 via the in/or route.

Treatment of either Swiss or DBA/2 mice with as little as 20 IU of Mu IFN- α injected ip resulted in a marked increase in 2'-5'-oligoadenylate synthetase activity in both peripheral blood mononuclear cells and splenocytes. In contrast, in the same experiment treatment of mice with up to 20,000 IU of Mu IFN- α via the in/or route did not significantly increase the expression of 2'-5'-oligoadenylate synthetase activity. Furthermore, treatment with 200 or 20,000 IU of either Mu IFN- α or Hu IFN- α 1-8 by the in/or route had no significant effect on 2'-5'-oligoadenylate synthetase activity at any of the time points tested up to 10 days after the start of IFN treatment.

Example 6 Bioavailability of Interferon Following Oromucosal Administration

In order to examine the bioavailability and pharmacokinetics of IFN, mice, which have the most favorable drug-blood volume ratio for such studies, were

treated with a single high dose of recombinant IFN- α labeled to the highest specific radioactivity possible with ^{125}I .

A pure preparation of 70×10^6 IU of Hu IFN- α 1-8 was taken up in 1.4 mls of PBS, and iodinated as described by Mogensen *et al*, (*Int. J. Cancer*, 1981
5 28: 575-582) using a modification of the chloramine-T method described by Hunter and Greenwood (*Nature*, 1962 194: 495-496).

The ^{125}I -labeled Hu IFN- α 1-8 (lot no. CGP35269-1) exhibited a biological activity of 2×10^7 IU/ml when assayed on human WISH cells challenged with VSV and 1×10^6 IU/ml when assayed on mouse L929 cells challenged with
10 VSV.

Six to seven week-old female Swiss mice were injected iv, ip, or treated in/or with 2×10^7 IU equivalent to 1×10^6 murine IU of ^{125}I Hu IFN- α 1-8 (1.0369×10^7 cpm/mouse). At the time points indicated, three mice per group were sacrificed, blood was collected, and the volume determined. Kidney, liver, lung,
15 spleen, and stomach/esophagus were harvested, blotted, and weighed to a precision of $\pm 1.0 \mu\text{g}$. The radioactivity of each sample was determined individually using a gamma counter. Whole blood was then separated by centrifugation ($800 \text{ g} \times 10 \text{ min.}$, 4°C), the serum was harvested, counted, and frozen at -80°C . The serum was then assayed for IFN content using a standard bioassay on both human WISH cells and on
20 mouse L929 cells as described above. The radioactive material present in the samples of serum was then isolated by affinity immunoprecipitation and analyzed by SDS-PAGE.

Very high levels of radioactivity ($> 2 \times 10^6$ cpm/ml) were detected in the peripheral blood of animals 5 min. after injection of 1.0369×10^7 cpm/mouse of ^{125}I -
25 labeled Hu IFN- α 1-8 by iv bolus. The amount of radioactivity present in whole blood then declined progressively at 15 and 30 min. The levels of radioactivity detected in the peripheral blood of animals 5 min. after ip injection of 1.0369×10^7 cpm of

¹²⁵I Hu IFN- α -1-8 were approximately twenty fold lower than the levels detected following an iv bolus. The levels of radioactivity then increased progressively at 15 and 30 min. post-injection. The levels of radioactivity detected in the blood of animals at 5, 10 or 15 min. after the in/or administration of ¹²⁵I IFN- α 1-8 were significantly lower than those detected at a given time following ip injection of the same quantity of radiolabelled IFN. For all three routes of administration, higher levels of radioactivity were detected in serum than in whole blood following in/or administration of ¹²⁵I-labeled IFN- α 1-8. The lower levels of radioactivity detected per ml of whole blood compared with the same volume of serum reflect the effectively larger volume of serum counted after removal of the cellular component of whole blood.

Samples of serum from all the mice in the study were assayed for the presence of biologically active IFN using a standard bioassay, as described above, and showed readily detectable levels of biologically active IFN in the serum of all the animals injected either iv or ip with ¹²⁵I Hu IFN- α 1-8 at all the time points tested. In contrast, no biologically active IFN was detected in the serum of any of the animals at any of the time points tested following the in/or administration of IFN, in spite of the presence of relatively high levels of radioactivity in the serum of these animals.

In order to determine whether the radioactive material detected in the serum of animals treated with ¹²⁵I Hu IFN- α 1-8 does indeed represent native IFN, the samples were immunoprecipitated with protein A-G Agarose, in order to precipitate immunoglobulins present in the samples, treated with an affinity-purified polyclonal anti-IFN- α antibody, and further immunoprecipitated. The samples were then subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) as described above.

SDS-PAGE analysis of the radioactive material in serum following iv or ip injection of ¹²⁵I Hu IFN- α 1-8 revealed a single homogenous band migrating with an electrophoretic mobility identical to that of uninjected ¹²⁵I Hu IFN- α 1-8. The apparent molecular weight of the material was estimated to be approximately 20000

Daltons, which corresponds exactly to the molecular weight of native Hu IFN- α 1-8. In contrast, none of the samples of serum from mice treated in/or with ^{125}I IFN- α 1-8 contained any material with an apparent molecular weight similar to that of native IFN, even though an identical quantity of radioactive material was loaded on to each gel.

The tissue distribution of radiolabelled material revealed very high levels of radioactivity in the kidneys, high levels in the liver, lung, and spleen of animals 5 min. after the iv injection of ^{125}I IFN- α 1-8. The level of radioactivity present in each of these four organs was then found to decrease progressively at 15 and 30 min. In contrast, the level of radioactivity in the stomach increased progressively at 15 and 30 min. to reach a level comparable to that present in the serum of animals 30 min. after an iv bolus.

Administration of ^{125}I IFN- α 1-8 by ip injection resulted in peak levels of radioactivity in all the tissues examined within 15 min., followed by a decline at 30 min. Similarly, in/or administration of ^{125}I Hu IFN- α 1-8 resulted in peak levels of radioactivity in all the tissues studied after 15 min. with some decline in the levels of radioactivity present at 30 min. The levels of radioactivity present in the stomach/esophagus were an order of magnitude greater than those detected in any other organ following the in/or administration of ^{125}I -labeled IFN- α 1-8, and were markedly higher than the levels present in these tissues following parenteral administration of the same quantity of radiolabelled Hu IFN- α 1-8 by either the iv or ip routes.

Example 7 Pharmacokinetics of Interferon Following Intranasal/Oral Administration

For precise determination of the pharmacokinetics of Hu IFN- α 1-8, mice were treated iv, ip or in/or with 1.0369×10^7 cpm/mouse of ^{125}I -labeled Hu IFN-

α 1-8, and the levels of radioactivity present in both whole blood and serum were determined at a series of time points over a 24 hour period.

The pharmacokinetic profile of ^{125}I -labeled Hu IFN- α 1-8 present in the blood of mice after an iv bolus closely followed a logarithmic clearance curve. This
5 agreed with results of a previous study carried out in mice using a closely related molecule, recombinant human α A/D (Bgl) (Bohoslawed *et al*; *J. IFN Res.*, 1986 6: 207-213). The amount of bioavailable material, calculated from the area under the curve of concentration versus time, was also similar to that for human α A/D. A biphasic time-consuming clearance curve was observed following an iv bolus of
10 ^{125}I IFN- α 1-8, which is characteristic of substances which are cleared through the kidneys, in agreement with the results of Example 6. The pharmacokinetics of ^{125}I -labeled IFN- α 1-8 following ip injection closely resembled those previously reported for IFNs administered im.

Readily detectable levels of biologically active IFN were present in the
15 serum of all the animals following either an iv bolus or ip injection of ^{125}I -labeled IFN- α 1-8.

1. Discussion of Anti-tumor Activity

The Friend erythroleukaemia model constitutes a very severe preclinical test of anti-tumor activity, since FLC are highly malignant and metastasize to both the
20 liver and spleen when injected iv. Indeed, results obtained using this model were the basis for the adoption of parenteral injection of IFN- α for treatment of human cancers. Thus, in all the experiments carried out in this study all the untreated animals and animals treated with control preparations died within 10 to 11 days. Injection of only 4 or 5 FLC cells will kill a mouse if no treatment is given. In contrast, some of the
25 animals treated with murine IFN- α by the oromucosal route are still alive more than 100 days after inoculation of 10^5 FLC, and may be considered to be cured.

Indeed, judging from previous work, IFN- α administered by the oromucosal route appears to be more effective than cyclophosphamide, 5-fluorouracil,

or methotrexate administered parenterally, which increase survival time by only a few days in animals injected with FLC (Gresser *et al*, *J. Natl. Cancer Inst.*, 1988 80: 126-131). Other drugs, such as cisplatin, vincristine, doxorubicin, bleomycin or etoposide are ineffective against this tumor (Gresser *et al*, *J. Natl. Cancer Inst.*, 1988 80: 126-131).

Similarly, IFN- α administered by the oromucosal route appears to be more effective against FLC than other cytokines such as IL-1 β , IL-2 and TNF- α administered systemically, which exhibit very little activity in this model.

Previous work has shown that IFN administered parenterally is one of the most active anti-tumor drugs in this model, and that IFN therapy is effective even when initiated after tumor metastases are already present in the liver (Gresser *et al*, *Intl. J. Cancer*, 1987 39: 789-792). The present results show that IFN administration by the oromucosal route is equally, or even more, effective.

Daily injections of IFN- α given together with a single dose of cyclophosphamide markedly increased the survival of lymphoma-bearing AKR mice compared to animals treated with either agent alone, when therapy was started after diagnosis of the lymphoma (Gresser *et al*, *Eur. J. Cancer*, 1978 14: 97-99). Successful combination therapy using IFN- α Z β and BCNU, *cis*-DDP (cisplatin), methotrexate, adriamycin, and α -difluoromethyl ornithine has also been reported in various pre-clinical animal tumor models. Combination therapy with 5-fluorouracil (5-FU) and IFN has also been reported to be of benefit in the treatment of metastatic colon cancer in man (Ernstoff *et al*, *Journal of Clinical Oncology*, 1989 7: 1764-1765). There are, however, other studies which have reported a decreased anti-tumor activity when IFN therapy was combined with the use of cyclophosphamide (Marquet *et al*, *Int. J. Cancer*, 1983 31: 223-226; Lee *et al*, *Biochem. Pharmacol.*, 1984 33: 4339-4443), adriamycin (Blackwill *et al*, *Cancer Res.*, 1984 44: 904-908), or 5-FU (Marquet *et al*, 1985 109: 156-158), *i.e.* precisely the same drugs which have been shown to exert a beneficial effect when used in combination with parenteral IFN

therapy. Combinations between IFN and other chemotherapy agents can readily be tested using methods described herein.

Combined interleukin-1 (IL-1) and IFN- α/β therapy results in a synergistic anti-tumor effect in mice injected with FLC (Belardelli *et al*, *Int. J. Cancer*, 1991 49: 274-278). The same treatment also exerts a marked anti-tumor effect against a metastatic variant (p11-R-Eb) of the Eb lymphoma, against which either agent alone is ineffective (Gabriele *et al*, *Invasion Metastasis*, 1993 13: 147-162). Of all the cytokines tested, IL-1 was found to be the most effective when combined with parenteral type I IFN therapy.

Combination therapy with the angiogenesis inhibitor AGM-1470 [(Chloroacetyl)-carbamic acid (3R-(3 α , 4 α (2R*, 3R*), 5 β , 6 β))-5-methoxy-4-(2-methyl-3-(3-methoxy-2-butenyl)oxiranyl)-1-oxaspiro(2.5)oct-6-yl ester] given together with IFN- α/β resulted in a markedly increased anti-tumor effect compared to that observed with either agent alone (Brem *et al*, *J. Pediatric Surgery*, 1993 28: 1253-1257).

It has been shown that hyperthermia enhances the anti-tumor action of IFN- α/β against the Lewis lung carcinoma (Yerushalmi *et al*, *Proc. Soc. Exp. Biol. Med.*, 1982 169: 413-415). Arginine butyrate has also been shown to potentiate the anti-tumor action of IFN- α (Chany and Cerutti, *Int. J. Cancer*, 1982 30: 489-493). Comparison of the degree of protection obtained when a given type and dose of IFN was administered by the oromucosal route compared to the results obtained following systemic administration (ip injection) showed that parenteral administration of IFN was in some cases marginally more effective, and in other cases no more effective, than oromucosal administration.

2. Discussion of Antiviral Activity

Although antiviral activity could not be detected in the serum of animals following in/or administration of ¹²⁵I IFN- α 1-8, Mu IFN- α/β and Mu IFN- α a statistically significant degree of protection against infection with a lethal dose of EMCV was nevertheless observed in these animals (Table 1).

Table I

The Effect of a Single Treatment with 125 I-IFN- α on the Survival
of Swiss Mice Injected with EMCV

Treatment group	Dose	Route	Number surviving animals / per group (Days post injection)									
			3	4	5	6	7	8	9	10	15	30
Untreated			6/6	4/6	2/6	0/6						
Hu IFN α 1-8	1.4x10 ⁵ IU	in/or	6/6	5/6	4/6	3/6	1/6	1/6	1/6	1/6	1/6	1/6
Mu IFN- α/β	6.4 x 10 ⁴ IU	in/or	6/6	5/6	5/6	4/6	3/6	2/6	2/6	2/6	1/6	1/6

Table 2

The Effect of a Single Treatment (once a day for 4 days) with Mu IFN- α on the Survival of Swiss Mice Injected with EMCV

Treatment group	Dose	Route	Number surviving animals / per group (Days post injection)											32
			3	4	5	6	7	8	9	10	15	30		
Untreated			10/10	9/10	4/10	0/10								
Mu IFN- α	2x10 ⁴ IU	in/or	10/10	10/10	10/10	10/10	10/10	10/10	10/10	9/10	7/10	7/10		

Our results obtained in a well-defined preclinical model of acute viral infection provided unequivocal evidence to support the "proof of principle" for the use of *high* dose oromucosal IFN for the therapy of acute systemic viral infections in man, and show that both a natural mixture of multiple IFN- α subtypes and a single recombinant IFN- α isotype (for example Mu IFN- α) exert statistically significant antiviral activity in this model. Natural Mu IFN- α/β and Hu IFN- α 1-8 appeared to be equally effective when administered oromucosally. Recombinant Mu IFN- β and Mu IFN- γ also show similar antiviral activity.

Comparison of the degree of protection obtained when a given type and dose of IFN was administered by the oromucosal route compared to the results obtained following systemic administration (ip injection) showed that parenteral administration of IFN was in some cases marginally more effective, and in other cases no more effective, than oromucosal administration.

3. General Discussion

The results of the biomarker pilot study show quite clearly that none of the three biomarkers tested (MHC class I antigen, Ly6 A/E antigen, and 2'-5'-oligoadenylate synthetase activity) adequately reflects the very marked biological activity (for example, antitumoral and antiviral activity) exhibited by IFN- α administered by the oromucosal route.

The contrast between the very marked increase in the expression of all three IFN-induced proteins observed in all the experiments undertaken following the ip injection of as little as 20 IU of IFN- α and the absence of any detectable effect following the administration of up to 20,000 IU of IFN- α via the oromucosal route is striking.

Although we cannot exclude the possibility that an effect on one or other of the biomarkers would have been observed at an earlier or intermediate time point, this seems to be unlikely, as IFN acts on the transcription of the genes coding for these

proteins and thus one would not expect to see an effect on any of these biomarkers until a number of hours after IFN treatment.

Again, although we cannot exclude the possibility that a systemic effect on one of the other numerous IFN-induced proteins would have been observed following treatment with IFN- α by the oromucosal route, this seems unlikely, as this would imply differential regulation of the expression of certain IFN-induced genes. It is entirely possible, however, that an effect on an IFN biomarker may be observed locally, for example, in nasal lymphocytes following administration of IFN- α via the oromucosal route.

In keeping with the absence of a detectable effect on the biomarkers studied, no consistent effect was observed on any of the hematological or blood chemistry parameters monitored during oromucosal IFN therapy, even in animals treated with up to 20,000 IU of IFN- α .

The results of the pharmacokinetics-bioactivity study show quite clearly that a statistically significant antiviral effect can be obtained following the oromucosal administration of a single dose of radiolabelled Hu IFN- α 1-8 under conditions where no circulating IFN can be detected in the peripheral blood, using methods of detection which are an order of magnitude more sensitive than those used previously. In keeping with these results the extent of the antiviral activity exerted by oromucosally administered IFN did appear to follow a classical dose-response relationship.

Readily detectable levels of radiolabelled material were found in both whole blood and serum of animals following oromucosal administration of ^{125}I -labeled IFN- α 1-8. These results contrast with the results of previous studies, which failed to detect IFN in the serum of animals even after the oral administration of large quantities of unlabelled IFN. However, the radioactive material detected in both whole blood and serum following oromucosal administration was biologically inactive. Furthermore, the results of SDS-PAGE analysis showed that this material

was of low molecular weight, and most probably reflected the absorption of degradation products following digestion of IFN in the stomach and small intestine. Analysis of the tissue distribution of radiolabelled material following oromucosal administration revealed markedly higher levels of radioactivity in the stomach than in
5 any of the other organs tested. Our results show quite clearly that even though biologically active IFN was not absorbed following oromucosal administration, this treatment does nevertheless exert a statistically significant antitumor and antiviral activity *in vivo*.

Without wishing to be bound by any proposed mechanism for the
10 observed beneficial effect, our results suggest that oromucosally administered IFN exerts its effects against tumor cells or against viruses via a presently undefined novel mechanism, which does not involve a direct action of exogenously administered IFN, or the induction of endogenous IFN. This is supported by the absence of detectable levels of circulatory IFN or of the three biomarkers tested. It appears that this
15 mechanism may act at least partly by stimulation of the abundant lymphoid tissue surrounding the nasopharyngeal and oral cavities. Since we have shown that oromucosal IFN is at least comparable in efficacy to systemically administered IFN, our results provide strong support for administration of IFN by the oromucosal route in the treatment of neoplastic or viral disease. This could have important implications
20 for the clinical use of IFN.

It will be apparent to the person skilled in the art that while the invention has been described in some detail for the purposes of clarity and understanding, various modifications and alterations to the embodiments and methods described
25 herein may be made without departing from the scope of the inventive concept disclosed in this specification.

WHAT IS CLAIMED IS:

1. A method for stimulating host defense mechanisms in a mammal which method comprises administering to the mammal a stimulating amount of an interferon via oromucosal contact, said amount being greater than about 20×10^6 IU of interferon.
5
2. A method for stimulating an immune response in a mammal which method comprises administering to the mammal an immunostimulating amount of an interferon via oromucosal contact, said amount being greater than about 20×10^6 IU of interferon.
10
3. A method of claim 1 in which the effective dose of interferon is administered in a single dose.
4. A method of claim 1 in which the effective non-toxic dose of interferon is
15 administered in a plurality of smaller doses over a period of time sufficient to elicit immunostimulation equivalent to that of a single dose.
5. A method of claim 1 in which an immunostimulating dose of interferon is administered continuously over a period of time sufficient to elicit immunostimulation
20 equivalent to that of a single dose.
6. A method for treating a neoplastic condition which method comprises administering to the mammal an effective amount of an interferon via oromucosal contact, said amount being in excess of a non-pathological dose of the same interferon
25 when parenterally administered.

7. A method for treating a viral infection which method comprises administering to the mammal an effective amount of an interferon via oromucosal contact, said amount being in excess of a non-pathological dose of the same interferon when parenterally administered.

5

8. A method of claim 1 wherein the interferon comprises a Type I interferon.

9. A method of claim 8 wherein the interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.

10

10. A method of claim 9 wherein the IFN- α comprises recombinant IFN- α .

11. A method of claim 1 wherein the interferon comprises a Type II interferon.

15 12. A method of claim 11 wherein the Type II interferon comprises γ -IFN.

13. A method of claim 6 wherein the neoplastic condition is of non-viral etiology.

14. A method for treating multiple myeloma, hairy cell leukemia, chronic
20 myelogenous leukemia, low grade lymphoma, cell lymphoma, carcinoid tumors, kidney tumors, renal cell carcinoma, hepatic cellular carcinoma, carcinomas, sarcomas, hematological malignancies, colorectal cancer, glioblastoma, lung cancer, colon cancer, and brain tumors including malignant brain tumors in a mammal which method comprises administering to the mammal a therapeutically effective amount of
25 an interferon via oromucosal contact, said amount being greater than about 20×10^6 IU.

15. A method of claim 14 in which the effective dose of interferon is administered in a single dose.
16. A method of claim 14 in which the effective dose of interferon is administered
5 in a plurality of smaller doses over a period of time sufficient to elicit a therapeutic response equivalent to that of a single dose.
17. A method of claim 14 in which the dose of interferon is administered continuously over a period of time sufficient to elicit a therapeutic response equivalent
10 to that of a single dose.
18. A method of claim 1 in which the total dose of interferon is from about 20×10^6 IU to about 1000×10^6 IU of interferon.
- 15 19. A method of claim 1 in which the dose of interferon is from about 20×10^6 IU to about 500×10^6 IU of interferon.
20. A method of claim 1 in which the dose of interferon is from about from about 50×10^6 IU to about 500×10^6 IU of interferon.
20
21. A method of claim 14 further comprising conjunctive radiation or chemotherapy.
22. A method of claim 14 further comprising the administration of other cytokines
25 or interferon inducers.
23. A method of claim 14 wherein the interferon comprises Type I interferon.

24. A method of claim 23 wherein the interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.
- 5 25. A method of claim 24 wherein the IFN- α comprises recombinant IFN- α .
26. A method of claim 14 wherein the interferon comprises Type II interferon.
27. A method of claim 26 wherein the interferon comprises γ interferon.
- 10 28. The use of interferon in the preparation of a medicament for oromucosal contact to stimulate host defense mechanisms or an immune response in a mammal which medicament comprises a stimulating amount of the interferon, said amount being greater than about 20×10^6 IU of interferon.
- 15 29. The use according to claim 28 in which the medicament comprises a single effective, non-toxic dose of the interferon.
30. The use according to claim 28 in which the medicament comprises a plurality
20 of smaller doses of the interferon sufficient to elicit a host defense or immune response stimulation equivalent to that of a single dose.
31. The use according to any one of claims 28-30 in which the medicament provides for continuous administration of a host defense or immune response
25 stimulating, non-toxic dose over a period of time sufficient to elicit host defense mechanisms or immune response stimulation equivalent to that of a single dose.

32. The use according to any one of claims 28-31 in which the medicament is adapted for treating or preventing a neoplastic condition, said amount being in excess of a non-pathological dose of the same interferon when parenterally administered.
- 5 33. The use according to any one of claims 28-31 in which the medicament is adapted for treating or preventing a viral infection, said amount being in excess of a non-pathological dose of the same interferon when parenterally administered.
34. The use according to any one of claims 28-33 in which the medicament
10 comprises an interferon and an interferon-inducer.
35. The use according to any one of claims 28-34 in which the medicament in unit dosage form comprises from about 20×10^6 IU to about 1000×10^6 IU of interferon.
- 15 36. The use according to any one of claims 28-35 in which the medicament includes another therapeutic agent for simultaneous, separate or sequential therapy.
37. The use according to any one of claims 28-36 in which the therapeutic agent is selected from the group consisting of cytostatic, anticancer, antiangiogenic, and
20 antiviral agents.
38. The use according to any one of claims 28-37 in which the interferon is a Type I interferon.
- 25 39. The use according to claim 38 in which the Type I interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.

40. The use according to claim 39 in which the Type I interferon is IFN- α .

41. The use according to any one of claims 28-37 in which the interferon is a Type II interferon.

5

42. The use according to claim 41 in which the Type II interferon is IFN- γ .

43. The use according to claim 38 or 41 in which the interferon is recombinant material.

10

44. Interferon composition for oromucosal contact to stimulate host defense mechanisms or an immune response in a mammal which composition comprises a stimulating amount of the interferon, said amount exceeding that which would elicit a pathological response when parenterally administered.

15

45. A composition of claim 44 which comprises a single effective, non-toxic dose of the interferon.

46. A composition of claim 44 which comprises a plurality of smaller doses of
20 interferon sufficient to elicit a host defense or immune response stimulation equivalent to that of a single dose.

47. A composition of any one of claims 44-46 which provides for continuous
administration of a host defense or immune response stimulating, non-toxic dose over
25 a period of time sufficient to elicit host defense or immune response stimulation
equivalent to that of a single dose.

48. A composition of any one of claims 44-47 adapted for treating a neoplastic condition.
49. A composition of any one of claims 44-47 adapted for treating a viral infection.
50. A composition of any one of claims 44-49 which comprises an interferon and an interferon-inducer.
51. A composition of any one of claims 44-50 in unit dosage form comprising from about 20×10^6 IU to about 1000×10^6 IU of interferon.
52. A composition of any one of claims 44-51 which includes another therapeutic agent for simultaneous, separate or sequential therapy.
53. A composition of any one of claims 44-52 in which the therapeutic agent is selected from the group consisting of cytostatic, anticancer, antiangiogenic, and antiviral agents.
54. A composition of any one of claims 44-53 in which the interferon is a Type I interferon.
55. A composition of claim 54 in which the Type I interferon is selected from the group consisting of IFN- α , IFN- β , IFN- ω , consensus IFN, and mixtures thereof.
56. A composition of claim 55 in which the Type I interferon is IFN- α .

57. A composition of any of claims 44-53 in which the interferon is a Type II interferon.

58. A composition of claim 57 in which the Type II interferon is IFN- γ .

5

59. A composition of claim 54 or 57 in which the interferon is recombinant material.

60. A pharmaceutical composition in unit dosage form adapted for oromucosal
10 administration comprising from about 20×10^6 IU to about 1000×10^6 IU of
interferon and a pharmaceutically acceptable carrier.

61. A composition of claim 60 comprising from about 20×10^6 IU to about 500×10^6 IU of interferon.

15

62. A composition of claim 61 comprising from about 50×10^6 IU to about 500×10^6 IU of interferon.

INTERNATIONAL SEARCH REPORT

International Application No.
PCT/IB 97/00490

A. CLASSIFICATION OF SUBJECT MATTER																						
Int Cl ⁶ : A61K 38/21																						
According to International Patent Classification (IPC) or to both national classification and IPC																						
B. FIELDS SEARCHED																						
Minimum documentation searched (classification system followed by classification symbols) See keywords as set out below																						
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																						
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Derwent, Chemical Abstracts. Keywords: Interferon, oral, buccal, mouth, nasal, nose, intranasal, mucosa, mucous, oromucosa																						
C. DOCUMENTS CONSIDERED TO BE RELEVANT																						
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																				
X	US 5286748 A (GEORGE A. EBY, III) 15 February 1994 (see whole document)	1-5, 7-12, 18, 19, 28-31, 33-47, 49-61																				
X	US 4605555 A (MITSUNOBU SATO, TOKUSHIMA ET AL) 12 August 1986 (see whole document)	1-5, 7-12, 18-20, 28-31, 33-47, 49-62																				
X	AU 12227/88 A1 (AMARILLO CELL CULTURE COMPANY, INC) 19 May 1988 (see whole document)	6, 7																				
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex																						
<p>* Special categories of cited documents:</p> <table border="0"> <tr> <td>"A"</td> <td>document defining the general state of the art which is not considered to be of particular relevance</td> <td>"T"</td> <td>later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"E"</td> <td>earlier document but published on or after the international filing date</td> <td>"X"</td> <td>document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> </tr> <tr> <td>"I."</td> <td>document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"Y"</td> <td>document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> </tr> <tr> <td>"O"</td> <td>document referring to an oral disclosure, use, exhibition or other means</td> <td>"&"</td> <td>document member of the same patent family</td> </tr> <tr> <td>"P"</td> <td>document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone	"I."	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art	"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family	"P"	document published prior to the international filing date but later than the priority date claimed		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																			
"E"	earlier document but published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"I."	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family																			
"P"	document published prior to the international filing date but later than the priority date claimed																					
Date of the actual completion of the international search 1 July 1997		Date of mailing of the international search report 26 AUG 1997																				
Name and mailing address of the ISA/AU AUSTRALIAN INDUSTRIAL PROPERTY ORGANISATION PO BOX 200 WODEN ACT 2606 AUSTRALIA Facsimile No.: (06) 285 3929		Authorized officer BERNARD NUTT Telephone No.: (06) 283 2491																				

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/IB 97/00490

C (Continuation)

DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	The Journal of Infectious Diseases, vol. 148, No. 3, Sept 1983, Samo T.C. <u>et al</u> "Efficacy and Tolerance of Intranasally Applied Recombinant Leukocyte A Interferon in Normal Volunteers." (see whole document)	7
A	The Journal of Infectious Diseases, vol. 148, No. 5, Nov 1983, Hayden F.G. <u>et al</u> "Human Tolerance and Histopathological Effects of Long-Term Administration of Intranasal Interferon - α 2." (see whole document)	1-62
X	The Journal of Infectious Diseases, Vol. 148, No. 3, Sept 1983, Hayden F.G. <u>et al</u> "Intranasal Interferon α 2 for Prevention of Rhinovirus Infection and Illness." (see whole document)	1-5, 7-12, 18, 19, 28-31, 33-47, 49-61

International Application No.
PCT/IB 97/00490

Patent Document Cited in Search Report				Patent Family Member			
US	5286748	AU WO	91620/91 9210997	CA	2099670	EP	566638
US	4605555	NONE					
AU	12227/88	AT	102047	CA	1320905	DE	3789239
		DK	3743/88	EP	341258	HK	246/95
		KR	9603377	NO	882983	NZ	222457
		WO	8803411	ZA	8708295	US	5019382